Fortress and its majority-owned subsidiary, Cyprium Therapeutics, said the FDA has accepted an NDA resubmission for CUTX-101, or copper histidinate, a treatment for children who suffer from Menkes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback